Alnylam Makes Entry Into Chinese RNAi Market
This article was originally published in The Pink Sheet Daily
Cambridge, Mass., biopharma adds to Asian presence begun with Japanese licensing deal in October.
You may also be interested in...
“We’ve just scratched the surface” regarding plans for Asia, Alnylam Director of External Alliances Zimmerman tells “The Pink Sheet” DAILY.
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?